ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Afatinib Dimaleate Market Research Report 2025
Published Date: July 2025
|
Report Code: QYRE-Auto-7S10509
Home | Market Reports | Health| Health Conditions| Cancer
Global Afatinib Dimaleate Market Insights Forecast to 2028
BUY CHAPTERS

Global Afatinib Dimaleate Market Research Report 2025

Code: QYRE-Auto-7S10509
Report
July 2025
Pages:87
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Kelun－Kazpharm
Qilu Pharmaceutical
Boehringer Ingelheim
CSPC Pharmaceutical
Merck
Hansoh Pharmaceuticak
Beacon Pharmaceuticals
Qingfeng Medicine Group
Yangtze River Pharm
Chia Tai Tianqing

Afatinib Dimaleate Market

The global market for Afatinib Dimaleate was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Afatinib dimaleate is an oral molecular targeted drug developed and produced by Boehringer Ingelheim, Germany. It is a TKIs with strong and irreversible dual inhibitory effect on EGFR and HER2, and was approved by THE US FDA in July 2013.It is not only suitable for first-line treatment of metastatic NSCLC with EGFR exon 19 deletion mutation or exon 21 (L858R) replacement mutation, but also a second - and third-line target drug for egFR-TKIS resistance.
In recent years, Alfatinib maleate has become a highly anticipated topic in the field of cancer. As a targeted therapeutic drug, it can help control the spread and growth of many cancers, such as non-small cell lung cancer, breast cancer, liver cancer, kidney cancer, stomach cancer, colorectal cancer, etc.
As a second-generation drug, afatinib maleate has good development prospects. For patients, afatinib maleate provides them with more and better treatment options; For pharmaceutical companies, afatinib maleate is a potential best-selling product worth developing.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Afatinib Dimaleate, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Afatinib Dimaleate.
The Afatinib Dimaleate market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Afatinib Dimaleate market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Afatinib Dimaleate manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Afatinib Dimaleate Market Report

Report Metric Details
Report Name Afatinib Dimaleate Market
Segment by Type
  • 20 mg
  • 30 mg
  • 40 mg
Segment by Application
  • Hospital
  • Clinic
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Kelun－Kazpharm, Qilu Pharmaceutical, Boehringer-Ingelheim, CSPC Pharmaceutical, Merck, Hansoh Pharmaceuticak, Beacon Pharmaceuticals, Qingfeng Medicine Group, Yangtze River Pharm, Chia Tai-Tianqing
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Afatinib Dimaleate manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Afatinib Dimaleate in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Afatinib Dimaleate Market report?

Ans: The main players in the Afatinib Dimaleate Market are Kelun－Kazpharm, Qilu Pharmaceutical, Boehringer-Ingelheim, CSPC Pharmaceutical, Merck, Hansoh Pharmaceuticak, Beacon Pharmaceuticals, Qingfeng Medicine Group, Yangtze River Pharm, Chia Tai-Tianqing

What are the Application segmentation covered in the Afatinib Dimaleate Market report?

Ans: The Applications covered in the Afatinib Dimaleate Market report are Hospital, Clinic

What are the Type segmentation covered in the Afatinib Dimaleate Market report?

Ans: The Types covered in the Afatinib Dimaleate Market report are 20 mg, 30 mg, 40 mg

1 Afatinib Dimaleate Market Overview
1.1 Product Definition
1.2 Afatinib Dimaleate by Type
1.2.1 Global Afatinib Dimaleate Market Value Comparison by Type (2024 VS 2031)
1.2.2 20 mg
1.2.3 30 mg
1.2.4 40 mg
1.3 Afatinib Dimaleate by Application
1.3.1 Global Afatinib Dimaleate Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Clinic
1.4 Global Afatinib Dimaleate Market Size Estimates and Forecasts
1.4.1 Global Afatinib Dimaleate Revenue 2020-2031
1.4.2 Global Afatinib Dimaleate Sales 2020-2031
1.4.3 Global Afatinib Dimaleate Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Afatinib Dimaleate Market Competition by Manufacturers
2.1 Global Afatinib Dimaleate Sales Market Share by Manufacturers (2020-2025)
2.2 Global Afatinib Dimaleate Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Afatinib Dimaleate Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Afatinib Dimaleate, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Afatinib Dimaleate, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Afatinib Dimaleate, Product Type & Application
2.7 Global Key Manufacturers of Afatinib Dimaleate, Date of Enter into This Industry
2.8 Global Afatinib Dimaleate Market Competitive Situation and Trends
2.8.1 Global Afatinib Dimaleate Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Afatinib Dimaleate Players Market Share by Revenue
2.8.3 Global Afatinib Dimaleate Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Afatinib Dimaleate Market Scenario by Region
3.1 Global Afatinib Dimaleate Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Afatinib Dimaleate Sales by Region: 2020-2031
3.2.1 Global Afatinib Dimaleate Sales by Region: 2020-2025
3.2.2 Global Afatinib Dimaleate Sales by Region: 2026-2031
3.3 Global Afatinib Dimaleate Revenue by Region: 2020-2031
3.3.1 Global Afatinib Dimaleate Revenue by Region: 2020-2025
3.3.2 Global Afatinib Dimaleate Revenue by Region: 2026-2031
3.4 North America Afatinib Dimaleate Market Facts & Figures by Country
3.4.1 North America Afatinib Dimaleate Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Afatinib Dimaleate Sales by Country (2020-2031)
3.4.3 North America Afatinib Dimaleate Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Afatinib Dimaleate Market Facts & Figures by Country
3.5.1 Europe Afatinib Dimaleate Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Afatinib Dimaleate Sales by Country (2020-2031)
3.5.3 Europe Afatinib Dimaleate Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Afatinib Dimaleate Market Facts & Figures by Region
3.6.1 Asia Pacific Afatinib Dimaleate Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Afatinib Dimaleate Sales by Region (2020-2031)
3.6.3 Asia Pacific Afatinib Dimaleate Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Afatinib Dimaleate Market Facts & Figures by Country
3.7.1 Latin America Afatinib Dimaleate Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Afatinib Dimaleate Sales by Country (2020-2031)
3.7.3 Latin America Afatinib Dimaleate Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Afatinib Dimaleate Market Facts & Figures by Country
3.8.1 Middle East and Africa Afatinib Dimaleate Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Afatinib Dimaleate Sales by Country (2020-2031)
3.8.3 Middle East and Africa Afatinib Dimaleate Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Afatinib Dimaleate Sales by Type (2020-2031)
4.1.1 Global Afatinib Dimaleate Sales by Type (2020-2025)
4.1.2 Global Afatinib Dimaleate Sales by Type (2026-2031)
4.1.3 Global Afatinib Dimaleate Sales Market Share by Type (2020-2031)
4.2 Global Afatinib Dimaleate Revenue by Type (2020-2031)
4.2.1 Global Afatinib Dimaleate Revenue by Type (2020-2025)
4.2.2 Global Afatinib Dimaleate Revenue by Type (2026-2031)
4.2.3 Global Afatinib Dimaleate Revenue Market Share by Type (2020-2031)
4.3 Global Afatinib Dimaleate Price by Type (2020-2031)
5 Segment by Application
5.1 Global Afatinib Dimaleate Sales by Application (2020-2031)
5.1.1 Global Afatinib Dimaleate Sales by Application (2020-2025)
5.1.2 Global Afatinib Dimaleate Sales by Application (2026-2031)
5.1.3 Global Afatinib Dimaleate Sales Market Share by Application (2020-2031)
5.2 Global Afatinib Dimaleate Revenue by Application (2020-2031)
5.2.1 Global Afatinib Dimaleate Revenue by Application (2020-2025)
5.2.2 Global Afatinib Dimaleate Revenue by Application (2026-2031)
5.2.3 Global Afatinib Dimaleate Revenue Market Share by Application (2020-2031)
5.3 Global Afatinib Dimaleate Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Kelun－Kazpharm
6.1.1 Kelun－Kazpharm Company Information
6.1.2 Kelun－Kazpharm Description and Business Overview
6.1.3 Kelun－Kazpharm Afatinib Dimaleate Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Kelun－Kazpharm Afatinib Dimaleate Product Portfolio
6.1.5 Kelun－Kazpharm Recent Developments/Updates
6.2 Qilu Pharmaceutical
6.2.1 Qilu Pharmaceutical Company Information
6.2.2 Qilu Pharmaceutical Description and Business Overview
6.2.3 Qilu Pharmaceutical Afatinib Dimaleate Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Qilu Pharmaceutical Afatinib Dimaleate Product Portfolio
6.2.5 Qilu Pharmaceutical Recent Developments/Updates
6.3 Boehringer-Ingelheim
6.3.1 Boehringer-Ingelheim Company Information
6.3.2 Boehringer-Ingelheim Description and Business Overview
6.3.3 Boehringer-Ingelheim Afatinib Dimaleate Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Boehringer-Ingelheim Afatinib Dimaleate Product Portfolio
6.3.5 Boehringer-Ingelheim Recent Developments/Updates
6.4 CSPC Pharmaceutical
6.4.1 CSPC Pharmaceutical Company Information
6.4.2 CSPC Pharmaceutical Description and Business Overview
6.4.3 CSPC Pharmaceutical Afatinib Dimaleate Sales, Revenue and Gross Margin (2020-2025)
6.4.4 CSPC Pharmaceutical Afatinib Dimaleate Product Portfolio
6.4.5 CSPC Pharmaceutical Recent Developments/Updates
6.5 Merck
6.5.1 Merck Company Information
6.5.2 Merck Description and Business Overview
6.5.3 Merck Afatinib Dimaleate Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Merck Afatinib Dimaleate Product Portfolio
6.5.5 Merck Recent Developments/Updates
6.6 Hansoh Pharmaceuticak
6.6.1 Hansoh Pharmaceuticak Company Information
6.6.2 Hansoh Pharmaceuticak Description and Business Overview
6.6.3 Hansoh Pharmaceuticak Afatinib Dimaleate Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Hansoh Pharmaceuticak Afatinib Dimaleate Product Portfolio
6.6.5 Hansoh Pharmaceuticak Recent Developments/Updates
6.7 Beacon Pharmaceuticals
6.7.1 Beacon Pharmaceuticals Company Information
6.7.2 Beacon Pharmaceuticals Description and Business Overview
6.7.3 Beacon Pharmaceuticals Afatinib Dimaleate Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Beacon Pharmaceuticals Afatinib Dimaleate Product Portfolio
6.7.5 Beacon Pharmaceuticals Recent Developments/Updates
6.8 Qingfeng Medicine Group
6.8.1 Qingfeng Medicine Group Company Information
6.8.2 Qingfeng Medicine Group Description and Business Overview
6.8.3 Qingfeng Medicine Group Afatinib Dimaleate Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Qingfeng Medicine Group Afatinib Dimaleate Product Portfolio
6.8.5 Qingfeng Medicine Group Recent Developments/Updates
6.9 Yangtze River Pharm
6.9.1 Yangtze River Pharm Company Information
6.9.2 Yangtze River Pharm Description and Business Overview
6.9.3 Yangtze River Pharm Afatinib Dimaleate Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Yangtze River Pharm Afatinib Dimaleate Product Portfolio
6.9.5 Yangtze River Pharm Recent Developments/Updates
6.10 Chia Tai-Tianqing
6.10.1 Chia Tai-Tianqing Company Information
6.10.2 Chia Tai-Tianqing Description and Business Overview
6.10.3 Chia Tai-Tianqing Afatinib Dimaleate Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Chia Tai-Tianqing Afatinib Dimaleate Product Portfolio
6.10.5 Chia Tai-Tianqing Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Afatinib Dimaleate Industry Chain Analysis
7.2 Afatinib Dimaleate Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Afatinib Dimaleate Production Mode & Process Analysis
7.4 Afatinib Dimaleate Sales and Marketing
7.4.1 Afatinib Dimaleate Sales Channels
7.4.2 Afatinib Dimaleate Distributors
7.5 Afatinib Dimaleate Customer Analysis
8 Afatinib Dimaleate Market Dynamics
8.1 Afatinib Dimaleate Industry Trends
8.2 Afatinib Dimaleate Market Drivers
8.3 Afatinib Dimaleate Market Challenges
8.4 Afatinib Dimaleate Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Kelun－Kazpharm
Qilu Pharmaceutical
Boehringer Ingelheim
CSPC Pharmaceutical
Merck
Hansoh Pharmaceuticak
Beacon Pharmaceuticals
Qingfeng Medicine Group
Yangtze River Pharm
Chia Tai Tianqing
List of Tables
 Table 1. Global Afatinib Dimaleate Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Afatinib Dimaleate Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Afatinib Dimaleate Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Afatinib Dimaleate Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Afatinib Dimaleate Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Afatinib Dimaleate Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Afatinib Dimaleate Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Afatinib Dimaleate Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Afatinib Dimaleate, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Afatinib Dimaleate, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Afatinib Dimaleate, Product Type & Application
 Table 12. Global Key Manufacturers of Afatinib Dimaleate, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Afatinib Dimaleate by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Afatinib Dimaleate as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Afatinib Dimaleate Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Afatinib Dimaleate Sales by Region (2020-2025) & (K Units)
 Table 18. Global Afatinib Dimaleate Sales Market Share by Region (2020-2025)
 Table 19. Global Afatinib Dimaleate Sales by Region (2026-2031) & (K Units)
 Table 20. Global Afatinib Dimaleate Sales Market Share by Region (2026-2031)
 Table 21. Global Afatinib Dimaleate Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Afatinib Dimaleate Revenue Market Share by Region (2020-2025)
 Table 23. Global Afatinib Dimaleate Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Afatinib Dimaleate Revenue Market Share by Region (2026-2031)
 Table 25. North America Afatinib Dimaleate Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Afatinib Dimaleate Sales by Country (2020-2025) & (K Units)
 Table 27. North America Afatinib Dimaleate Sales by Country (2026-2031) & (K Units)
 Table 28. North America Afatinib Dimaleate Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Afatinib Dimaleate Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Afatinib Dimaleate Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Afatinib Dimaleate Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Afatinib Dimaleate Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Afatinib Dimaleate Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Afatinib Dimaleate Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Afatinib Dimaleate Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Afatinib Dimaleate Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Afatinib Dimaleate Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Afatinib Dimaleate Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Afatinib Dimaleate Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Afatinib Dimaleate Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Afatinib Dimaleate Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Afatinib Dimaleate Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Afatinib Dimaleate Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Afatinib Dimaleate Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Afatinib Dimaleate Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Afatinib Dimaleate Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Afatinib Dimaleate Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Afatinib Dimaleate Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Afatinib Dimaleate Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Afatinib Dimaleate Sales (K Units) by Type (2020-2025)
 Table 51. Global Afatinib Dimaleate Sales (K Units) by Type (2026-2031)
 Table 52. Global Afatinib Dimaleate Sales Market Share by Type (2020-2025)
 Table 53. Global Afatinib Dimaleate Sales Market Share by Type (2026-2031)
 Table 54. Global Afatinib Dimaleate Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Afatinib Dimaleate Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Afatinib Dimaleate Revenue Market Share by Type (2020-2025)
 Table 57. Global Afatinib Dimaleate Revenue Market Share by Type (2026-2031)
 Table 58. Global Afatinib Dimaleate Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Afatinib Dimaleate Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Afatinib Dimaleate Sales (K Units) by Application (2020-2025)
 Table 61. Global Afatinib Dimaleate Sales (K Units) by Application (2026-2031)
 Table 62. Global Afatinib Dimaleate Sales Market Share by Application (2020-2025)
 Table 63. Global Afatinib Dimaleate Sales Market Share by Application (2026-2031)
 Table 64. Global Afatinib Dimaleate Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Afatinib Dimaleate Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Afatinib Dimaleate Revenue Market Share by Application (2020-2025)
 Table 67. Global Afatinib Dimaleate Revenue Market Share by Application (2026-2031)
 Table 68. Global Afatinib Dimaleate Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Afatinib Dimaleate Price (US$/Unit) by Application (2026-2031)
 Table 70. Kelun－Kazpharm Company Information
 Table 71. Kelun－Kazpharm Description and Business Overview
 Table 72. Kelun－Kazpharm Afatinib Dimaleate Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. Kelun－Kazpharm Afatinib Dimaleate Product
 Table 74. Kelun－Kazpharm Recent Developments/Updates
 Table 75. Qilu Pharmaceutical Company Information
 Table 76. Qilu Pharmaceutical Description and Business Overview
 Table 77. Qilu Pharmaceutical Afatinib Dimaleate Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Qilu Pharmaceutical Afatinib Dimaleate Product
 Table 79. Qilu Pharmaceutical Recent Developments/Updates
 Table 80. Boehringer-Ingelheim Company Information
 Table 81. Boehringer-Ingelheim Description and Business Overview
 Table 82. Boehringer-Ingelheim Afatinib Dimaleate Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Boehringer-Ingelheim Afatinib Dimaleate Product
 Table 84. Boehringer-Ingelheim Recent Developments/Updates
 Table 85. CSPC Pharmaceutical Company Information
 Table 86. CSPC Pharmaceutical Description and Business Overview
 Table 87. CSPC Pharmaceutical Afatinib Dimaleate Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. CSPC Pharmaceutical Afatinib Dimaleate Product
 Table 89. CSPC Pharmaceutical Recent Developments/Updates
 Table 90. Merck Company Information
 Table 91. Merck Description and Business Overview
 Table 92. Merck Afatinib Dimaleate Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Merck Afatinib Dimaleate Product
 Table 94. Merck Recent Developments/Updates
 Table 95. Hansoh Pharmaceuticak Company Information
 Table 96. Hansoh Pharmaceuticak Description and Business Overview
 Table 97. Hansoh Pharmaceuticak Afatinib Dimaleate Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Hansoh Pharmaceuticak Afatinib Dimaleate Product
 Table 99. Hansoh Pharmaceuticak Recent Developments/Updates
 Table 100. Beacon Pharmaceuticals Company Information
 Table 101. Beacon Pharmaceuticals Description and Business Overview
 Table 102. Beacon Pharmaceuticals Afatinib Dimaleate Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. Beacon Pharmaceuticals Afatinib Dimaleate Product
 Table 104. Beacon Pharmaceuticals Recent Developments/Updates
 Table 105. Qingfeng Medicine Group Company Information
 Table 106. Qingfeng Medicine Group Description and Business Overview
 Table 107. Qingfeng Medicine Group Afatinib Dimaleate Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. Qingfeng Medicine Group Afatinib Dimaleate Product
 Table 109. Qingfeng Medicine Group Recent Developments/Updates
 Table 110. Yangtze River Pharm Company Information
 Table 111. Yangtze River Pharm Description and Business Overview
 Table 112. Yangtze River Pharm Afatinib Dimaleate Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 113. Yangtze River Pharm Afatinib Dimaleate Product
 Table 114. Yangtze River Pharm Recent Developments/Updates
 Table 115. Chia Tai-Tianqing Company Information
 Table 116. Chia Tai-Tianqing Description and Business Overview
 Table 117. Chia Tai-Tianqing Afatinib Dimaleate Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 118. Chia Tai-Tianqing Afatinib Dimaleate Product
 Table 119. Chia Tai-Tianqing Recent Developments/Updates
 Table 120. Key Raw Materials Lists
 Table 121. Raw Materials Key Suppliers Lists
 Table 122. Afatinib Dimaleate Distributors List
 Table 123. Afatinib Dimaleate Customers List
 Table 124. Afatinib Dimaleate Market Trends
 Table 125. Afatinib Dimaleate Market Drivers
 Table 126. Afatinib Dimaleate Market Challenges
 Table 127. Afatinib Dimaleate Market Restraints
 Table 128. Research Programs/Design for This Report
 Table 129. Key Data Information from Secondary Sources
 Table 130. Key Data Information from Primary Sources
 Table 131. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Afatinib Dimaleate
 Figure 2. Global Afatinib Dimaleate Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Afatinib Dimaleate Market Share by Type: 2024 & 2031
 Figure 4. 20 mg Product Picture
 Figure 5. 30 mg Product Picture
 Figure 6. 40 mg Product Picture
 Figure 7. Global Afatinib Dimaleate Market Value by Application (2020-2031) & (US$ Million)
 Figure 8. Global Afatinib Dimaleate Market Share by Application: 2024 & 2031
 Figure 9. Hospital
 Figure 10. Clinic
 Figure 11. Global Afatinib Dimaleate Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 12. Global Afatinib Dimaleate Market Size (2020-2031) & (US$ Million)
 Figure 13. Global Afatinib Dimaleate Sales (2020-2031) & (K Units)
 Figure 14. Global Afatinib Dimaleate Average Price (US$/Unit) & (2020-2031)
 Figure 15. Afatinib Dimaleate Report Years Considered
 Figure 16. Afatinib Dimaleate Sales Share by Manufacturers in 2024
 Figure 17. Global Afatinib Dimaleate Revenue Share by Manufacturers in 2024
 Figure 18. Global 5 and 10 Largest Afatinib Dimaleate Players: Market Share by Revenue in Afatinib Dimaleate in 2024
 Figure 19. Afatinib Dimaleate Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 20. Global Afatinib Dimaleate Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 21. North America Afatinib Dimaleate Sales Market Share by Country (2020-2031)
 Figure 22. North America Afatinib Dimaleate Revenue Market Share by Country (2020-2031)
 Figure 23. United States Afatinib Dimaleate Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 24. Canada Afatinib Dimaleate Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 25. Europe Afatinib Dimaleate Sales Market Share by Country (2020-2031)
 Figure 26. Europe Afatinib Dimaleate Revenue Market Share by Country (2020-2031)
 Figure 27. Germany Afatinib Dimaleate Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. France Afatinib Dimaleate Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. U.K. Afatinib Dimaleate Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Italy Afatinib Dimaleate Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Russia Afatinib Dimaleate Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Asia Pacific Afatinib Dimaleate Sales Market Share by Region (2020-2031)
 Figure 33. Asia Pacific Afatinib Dimaleate Revenue Market Share by Region (2020-2031)
 Figure 34. China Afatinib Dimaleate Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Japan Afatinib Dimaleate Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. South Korea Afatinib Dimaleate Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. India Afatinib Dimaleate Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. Australia Afatinib Dimaleate Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. China Taiwan Afatinib Dimaleate Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Indonesia Afatinib Dimaleate Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Thailand Afatinib Dimaleate Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Malaysia Afatinib Dimaleate Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Latin America Afatinib Dimaleate Sales Market Share by Country (2020-2031)
 Figure 44. Latin America Afatinib Dimaleate Revenue Market Share by Country (2020-2031)
 Figure 45. Mexico Afatinib Dimaleate Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Brazil Afatinib Dimaleate Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Argentina Afatinib Dimaleate Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Middle East and Africa Afatinib Dimaleate Sales Market Share by Country (2020-2031)
 Figure 49. Middle East and Africa Afatinib Dimaleate Revenue Market Share by Country (2020-2031)
 Figure 50. Turkey Afatinib Dimaleate Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Saudi Arabia Afatinib Dimaleate Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. UAE Afatinib Dimaleate Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Global Sales Market Share of Afatinib Dimaleate by Type (2020-2031)
 Figure 54. Global Revenue Market Share of Afatinib Dimaleate by Type (2020-2031)
 Figure 55. Global Afatinib Dimaleate Price (US$/Unit) by Type (2020-2031)
 Figure 56. Global Sales Market Share of Afatinib Dimaleate by Application (2020-2031)
 Figure 57. Global Revenue Market Share of Afatinib Dimaleate by Application (2020-2031)
 Figure 58. Global Afatinib Dimaleate Price (US$/Unit) by Application (2020-2031)
 Figure 59. Afatinib Dimaleate Value Chain
 Figure 60. Channels of Distribution (Direct Vs Distribution)
 Figure 61. Bottom-up and Top-down Approaches for This Report
 Figure 62. Data Triangulation
 Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Seventh Sense AI

SIMILAR REPORTS

Global Afatinib API Market Research Report 2024
Global EGFR TKI for Advanced NSCLC Market Research Report 2024
Global EGFR TKI Market Research Report 2024
Global Lapatinib Ditosylate API Market Research Report 2025
Global Lapatinib Market Insights Forecast to 2030
Anlotinib Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Research Report 2024
Global Icotinib API Market Research Report 2024
Global Targeted Drug HER2 Inhibitors for NSCLC Market Research Report 2024
Global Afatinib Market Research Report 2024
Icotinib Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Icotinib Hydrochloride Tablets Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Nilotinib Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Dacomitinib API Market Research Report 2024
Global Lapatinib Ditosylate Tablets Market Research Report 2024
Global Gilteritinib API Market Research Report 2024
Erlotinib Hydrochloride Tablet Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global TKI for Chronic Myeloid Leukemia Market Research Report 2024
Dasatinib Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Targeted Drug VEGFR2 Inhibitors for NSCLC Market Research Report 2024

RELATED REPORTS

Global Hormonal Therapy for Cancer Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-5L19798
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Cancer Insurance Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-28I6901
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-22R9736
Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Drugs for Differentiated Thyroid Cancer Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-29A2598
Tue Sep 09 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions